1:2 bonus shares & final dividend of Rs 1,81,60,877.50 after stock split from Rs 5 to Rs 1; Scrip trades at high ROE & high ROCE

The stock gave multibagger returns of 160 per cent in just 1 year, 670 per cent in 3 years and a whopping 5,000 per cent in just 5 years.

Gujarat Themis Biosyn Ltd announced that the Board of Directors of the company announced bonus shares in the ratio 1:2 i.e., 1 bonus share for every 2 equity shares held by the equity shareholders of the company as of record date. The bonus issue of equity shares is subject to the approval of the shareholders and the record date will be announced in due course. Additionally, the Board of Directors of the company recommended a final dividend for the Financial Year ended March 31, 2024, Rs 0.25 i.e. 25 per cent per equity share having a face value of Rs 1 aggregating to Rs 1,81,60,877.50.

Earlier, the shares of the company ex-traded a sub-division/ stock split of every 1 fully paid-up equity share having a face value of Rs 5 each in the authorised share capital of the company, into 5 fully paid-up equity shares having a face value of Rs 1 each as of record date. The ex-record date for the stock split was Tuesday, October 10, 2023.  

Also Read: Turnaround story in this penny stock at Rs 21.20 & promoters sold 11.55 per cent stake: This IT-company announces a 198 per cent jump in net profit!

Gujarat Themis Biosyn Ltd, established in 1981, specializes in the manufacturing and sale of finished Active Pharmaceutical Ingredients (APIs) through fermentation processes. This pharmaceutical company produces medicinal chemicals and is actively managed by Themis Medicare Ltd., a joint venture with Gedeon Richter Ltd. of Hungary. Gujarat Themis Biosyn Ltd also boasts a significant partnership through Technical and Financial collaboration with Yuhan Corporation of South Korea. Notably, it was the first company in India to initiate the commercial production of Rifampicin, an anti-tuberculosis drug.

The shares of the company have an ROE of 45.9 per cent and an ROCE of 61.1 per cent. The stock gave multibagger returns of 160 per cent in just 1 year, 670 per cent in 3 years and a whopping 5,000 per cent in just 5 years. Investors should keep an eye on this Small-Cap pharma stock.

Disclaimer: The article is for informational purposes only and not investment advice.